Arvinas (ARVN) financial statements

Healthcare · Biotechnology · Market cap $453M

Arvinas reported revenue of $263M in fiscal 2025, up 55.8% a year over 8 years.

Net income was -$81M and the operating margin -45.1%, against -326.7% in 2017.

Free cash flow was -$276M, and the company returned $92M in net buybacks.

The diluted share count rose 3636% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-0.5-0.200.20.50.8201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Arvinas's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Revenue$8M$14M$43M$26M$54M$131M$78M$263M$263M
Research and development$29M$45M$67M$108M$180M$315M$380M$348M$285M
Selling, general and admin$4M$13M$27M$38M$62M$80M$100M$165M$96M
Operating income-$25M-$44M-$52M-$121M-$188M-$263M-$402M-$250M-$118M
Interest expense$50,357$57,440$100,000$100,000$100,000$0$0$0—
Pre-tax income———-$115M-$184M-$251M-$364M-$198M-$80M
Income tax$0$0$0$0$0$21M$900,000$600,000$300,000
Net income-$24M-$41M-$70M-$119M-$191M-$282M-$367M-$199M-$81M
EPS (diluted)-$15.08-$25.45-$2.13-$3.02-$3.82-$5.31-$6.62-$2.77-$1.14
Diluted shares2M9M33M40M50M53M56M72M71M
Operating margin-326.7%-305.8%-119.8%-466.4%-351.5%-200.3%-511.5%-95.0%-45.1%
Net margin-317.3%-289.6%-163.5%-460.6%-356.3%-215.0%-467.9%-75.5%-30.8%

Balance sheet

Fiscal years, from Arvinas's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Cash and short-term investments$39M$188M$281M$689M$1.5B$1.2B$1.3B$1.0B$685M
Receivables$25M$3M—$1M$15M$1M$0$6M$1M
Total current assets$66M$196M$291M$703M$1.6B$1.2B$1.3B$1.1B$701M
Property, plant and equipment$1M$4M$8M$12M$13M$13M$12M$7M$5M
Total assets$67M$199M$302M$717M$1.6B$1.3B$1.3B$1.1B$718M
Total current liabilities$18M$23M$33M$49M$262M$295M$257M$230M$142M
Long-term debt$151,122$2M$2M$2M$1M$1M$800,000$600,000$400,000
Total liabilities$67M$63M$75M$75M$800M$704M$645M$530M$284M
Shareholders' equity-$61M$137M$227M$642M$782M$565M$660M$562M$434M
Net debt-$31M-$1M-$7M-$586M-$107M-$80M-$311M-$100M-$142M

Cash flow

Fiscal years, from Arvinas's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Operating cash flow$5M-$16M-$41M-$90M$559M-$274M-$348M-$259M-$274M
Capital spending$1M$3M$6M$6M$5M$7M$3M$2M$2M
Free cash flow$4M-$19M-$47M-$96M$555M-$280M-$351M-$261M-$276M
Stock-based compensation$245,048$12M$20M$30M$57M$76M$72M$88M$44M
Share buybacks (net)——————$0$0-$92M
Net borrowing-$161,363$2M-$200,000$0$0$0$0-$400,000-$200,000
Free cash flow margin54.1%-132.3%-109.1%-371.0%1034.9%-213.3%-446.8%-99.1%-105.0%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARVN.
Open ARVN in Investingly

Questions

What was Arvinas's revenue in 2025?

$263M in fiscal 2025, from its 10-K filing.

How much free cash flow does Arvinas generate?

-$276M in fiscal 2025 (operating cash flow minus capital spending).

From Arvinas's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.